vs
Consensus Cloud Solutions, Inc.（CCSI）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是Consensus Cloud Solutions, Inc.的1.1倍（$92.9M vs $87.1M），Vericel Corp净利率更高（25.0% vs 23.5%，领先1.5%），Vericel Corp同比增速更快（23.3% vs 0.1%），Vericel Corp自由现金流更多（$12.8M vs $7.3M），过去两年Vericel Corp的营收复合增速更高（34.6% vs -0.6%）
Consensus Cloud Solutions是一家云解决方案提供商，核心产品包括加密数字传真、安全文档交换、工作流程自动化工具，主要面向医疗、法律、金融服务等领域的北美企业客户提供相关服务。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
CCSI vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.1倍
$87.1M
营收增速更快
VCEL
高出23.2%
0.1%
净利率更高
VCEL
高出1.5%
23.5%
自由现金流更多
VCEL
多$5.5M
$7.3M
两年增速更快
VCEL
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $87.1M | $92.9M |
| 净利润 | $20.5M | $23.2M |
| 毛利率 | 80.0% | 78.7% |
| 营业利润率 | 41.1% | 24.1% |
| 净利率 | 23.5% | 25.0% |
| 营收同比 | 0.1% | 23.3% |
| 净利润同比 | 13.5% | 17.3% |
| 每股收益（稀释后） | $1.06 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCSIVCEL
| Q4 25 | $87.1M | $92.9M | ||
| Q3 25 | $87.8M | $67.5M | ||
| Q2 25 | $87.7M | $63.2M | ||
| Q1 25 | $87.1M | $52.6M | ||
| Q4 24 | $87.0M | $75.4M | ||
| Q3 24 | $87.8M | $57.9M | ||
| Q2 24 | $87.5M | $52.7M | ||
| Q1 24 | $88.1M | $51.3M |
净利润CCSIVCEL
| Q4 25 | $20.5M | $23.2M | ||
| Q3 25 | $22.1M | $5.1M | ||
| Q2 25 | $20.8M | $-553.0K | ||
| Q1 25 | $21.2M | $-11.2M | ||
| Q4 24 | $18.1M | $19.8M | ||
| Q3 24 | $21.1M | $-901.0K | ||
| Q2 24 | $23.9M | $-4.7M | ||
| Q1 24 | $26.4M | $-3.9M |
毛利率CCSIVCEL
| Q4 25 | 80.0% | 78.7% | ||
| Q3 25 | 80.0% | 73.5% | ||
| Q2 25 | 79.9% | 73.7% | ||
| Q1 25 | 79.3% | 69.0% | ||
| Q4 24 | 79.5% | 77.6% | ||
| Q3 24 | 79.9% | 71.9% | ||
| Q2 24 | 80.4% | 69.5% | ||
| Q1 24 | 80.7% | 68.9% |
营业利润率CCSIVCEL
| Q4 25 | 41.1% | 24.1% | ||
| Q3 25 | 43.2% | 5.1% | ||
| Q2 25 | 44.5% | -3.2% | ||
| Q1 25 | 43.0% | -24.3% | ||
| Q4 24 | 38.4% | 24.5% | ||
| Q3 24 | 43.8% | -4.3% | ||
| Q2 24 | 45.6% | -11.5% | ||
| Q1 24 | 42.7% | -10.7% |
净利率CCSIVCEL
| Q4 25 | 23.5% | 25.0% | ||
| Q3 25 | 25.2% | 7.5% | ||
| Q2 25 | 23.7% | -0.9% | ||
| Q1 25 | 24.3% | -21.4% | ||
| Q4 24 | 20.8% | 26.3% | ||
| Q3 24 | 24.1% | -1.6% | ||
| Q2 24 | 27.3% | -8.9% | ||
| Q1 24 | 29.9% | -7.5% |
每股收益（稀释后）CCSIVCEL
| Q4 25 | $1.06 | $0.46 | ||
| Q3 25 | $1.15 | $0.10 | ||
| Q2 25 | $1.07 | $-0.01 | ||
| Q1 25 | $1.07 | $-0.23 | ||
| Q4 24 | $0.92 | $0.40 | ||
| Q3 24 | $1.09 | $-0.02 | ||
| Q2 24 | $1.24 | $-0.10 | ||
| Q1 24 | $1.37 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.7M | $137.5M |
| 总债务越低越好 | $558.4M | — |
| 股东权益账面价值 | $13.8M | $354.6M |
| 总资产 | $663.8M | $488.0M |
| 负债/权益比越低杠杆越低 | 40.54× | — |
8季度趋势，按日历期对齐
现金及短期投资CCSIVCEL
| Q4 25 | $74.7M | $137.5M | ||
| Q3 25 | $97.6M | $135.4M | ||
| Q2 25 | $57.9M | $116.9M | ||
| Q1 25 | $53.4M | $112.9M | ||
| Q4 24 | $33.5M | $116.2M | ||
| Q3 24 | $54.6M | $101.7M | ||
| Q2 24 | $49.2M | $102.5M | ||
| Q1 24 | $61.5M | $110.6M |
总债务CCSIVCEL
| Q4 25 | $558.4M | — | ||
| Q3 25 | $578.6M | — | ||
| Q2 25 | $578.2M | — | ||
| Q1 25 | $583.7M | — | ||
| Q4 24 | $593.0M | — | ||
| Q3 24 | $612.5M | — | ||
| Q2 24 | $642.8M | — | ||
| Q1 24 | $671.7M | — |
股东权益CCSIVCEL
| Q4 25 | $13.8M | $354.6M | ||
| Q3 25 | $-2.6M | $321.9M | ||
| Q2 25 | $-26.5M | $306.8M | ||
| Q1 25 | $-49.4M | $295.5M | ||
| Q4 24 | $-79.5M | $292.0M | ||
| Q3 24 | $-93.2M | $257.5M | ||
| Q2 24 | $-124.4M | $243.0M | ||
| Q1 24 | $-151.8M | $233.9M |
总资产CCSIVCEL
| Q4 25 | $663.8M | $488.0M | ||
| Q3 25 | $675.0M | $453.3M | ||
| Q2 25 | $641.5M | $435.6M | ||
| Q1 25 | $629.6M | $424.6M | ||
| Q4 24 | $602.2M | $432.7M | ||
| Q3 24 | $622.5M | $390.4M | ||
| Q2 24 | $608.5M | $376.8M | ||
| Q1 24 | $620.8M | $356.7M |
负债/权益比CCSIVCEL
| Q4 25 | 40.54× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.2M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $7.3M | $12.8M |
| 自由现金流率自由现金流/营收 | 8.4% | 13.8% |
| 资本支出强度资本支出/营收 | 9.1% | 2.4% |
| 现金转化率经营现金流/净利润 | 0.74× | 0.65× |
| 过去12个月自由现金流最近4个季度 | $105.9M | $24.7M |
8季度趋势，按日历期对齐
经营现金流CCSIVCEL
| Q4 25 | $15.2M | $15.0M | ||
| Q3 25 | $51.6M | $22.1M | ||
| Q2 25 | $28.3M | $8.2M | ||
| Q1 25 | $40.9M | $6.6M | ||
| Q4 24 | $11.1M | $22.2M | ||
| Q3 24 | $41.6M | $10.2M | ||
| Q2 24 | $24.4M | $18.5M | ||
| Q1 24 | $44.7M | $7.2M |
自由现金流CCSIVCEL
| Q4 25 | $7.3M | $12.8M | ||
| Q3 25 | $44.4M | $19.5M | ||
| Q2 25 | $20.3M | $81.0K | ||
| Q1 25 | $33.7M | $-7.6M | ||
| Q4 24 | $3.1M | $8.5M | ||
| Q3 24 | $33.6M | $-9.2M | ||
| Q2 24 | $15.8M | $1.8M | ||
| Q1 24 | $35.8M | $-6.8M |
自由现金流率CCSIVCEL
| Q4 25 | 8.4% | 13.8% | ||
| Q3 25 | 50.6% | 28.8% | ||
| Q2 25 | 23.2% | 0.1% | ||
| Q1 25 | 38.7% | -14.5% | ||
| Q4 24 | 3.6% | 11.2% | ||
| Q3 24 | 38.3% | -15.9% | ||
| Q2 24 | 18.1% | 3.4% | ||
| Q1 24 | 40.6% | -13.3% |
资本支出强度CCSIVCEL
| Q4 25 | 9.1% | 2.4% | ||
| Q3 25 | 8.2% | 3.9% | ||
| Q2 25 | 9.1% | 12.9% | ||
| Q1 25 | 8.3% | 27.0% | ||
| Q4 24 | 9.2% | 18.3% | ||
| Q3 24 | 9.1% | 33.5% | ||
| Q2 24 | 9.8% | 31.8% | ||
| Q1 24 | 10.1% | 27.3% |
现金转化率CCSIVCEL
| Q4 25 | 0.74× | 0.65× | ||
| Q3 25 | 2.34× | 4.35× | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.94× | — | ||
| Q4 24 | 0.62× | 1.12× | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 1.02× | — | ||
| Q1 24 | 1.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCSI
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
